DV
Dividend Vision

HMTXF — Hemostemix Inc

Hemostemix Inc (HMTXF)

Total return is -99.7% over the past 10.6 years, 472.4 points behind SPY at 372.7%. Its deepest 1-year drawdown was 61.6%.

HMTX is a single-stock equity holding in Hemostemix Inc, a biotech company focused on cell therapy and regenerative medicine. The fund lacks a traditional dividend distribution rate and does not report an expense ratio, suggesting it may function primarily as a direct equity vehicle rather than a conventional dividend-focused ETF. This structure appeals primarily to investors seeking exposure to a specific biotech company rather than those focused on current income or dividend yields.

HMTXF key facts

Asset type
Stock
Asset class
Equity
Inception date
01/07/2016
Last close
$0.04
Market cap
$8,989,094
Average volume
0.0
Payment date
12/30/2020
Beta
0.61
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.01